Q32 Bio is a biotechnology company developing therapies targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. 

Biotechnology

Q32 Bio

Jodie Morrison

Eric Bell

Reena Malik

Justin Rogers

Joel Scherer

Isidora Tošić

Hong Wu, MD, PhD, DABT

Fei Liu

Theresa Carbeau

Dessi McEntee, MS, DABT

Bill Lundberg

David Appugliese

Maria Marzilli

Jason Campagna

Shelia Violette

The Scientific Research & Development team at Q32 Bio is dedicated to advancing innovative therapies that target key regulators of the immune system. Comprising experts in pharmacology, protein science, and translational biology, the team collaborates to design and execute preclinical studies, develop cutting-edge biologics, and navigate regulatory processes. Their goal is to translate scientific discoveries into effective treatments for autoimmune and inflammatory diseases.

Scientific Research & Development

Finance & Strategic Planning

Leadership Team

Scientific Research & Development

About

Team members

Other teams at Q32 Bio

Finance & Strategic Planning

Leadership Team